Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Accounting Standard: International Financial Reporting Standards (IFRS)
Pharming Group is a global biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases. The company operates two main commercial products: RUCONEST® (recombinant C1 esterase inhibitor for Hereditary Angioedema) and Joenja® (leniolisib for Activated PI3K-Delta Syndrome). In 2025, the company completed the acquisition of Abliva AB, adding napazimone (KL1333) for primary mitochondrial disease to its late-stage pipeline. The company withdrew RUCONEST® from commercialization in non-U.S. markets to focus resources on the U.S. market and pipeline advancement.
Key Financial Metrics
| Metric ($ millions) | 2025 | 2024 | Change |
|---|---|---|---|
| Revenues | 376.1 | 297.2 | +26.6% |
| Gross Profit | 330.6 | 261.8 | +26.3% |
| Operating Profit | 25.8 | (8.6) | Turnaround to Profit |
| Net Profit (Loss) | 2.5 | (11.8) | Turnaround to Profit |
| Operating Cash Flow | 54.7 | (1.8) | Significant Improvement |
| Cash & Marketable Securities | 179.1 | 167.9 | +6.6% |
| Net Debt | (83.0) | (87.0) | Net Cash Position |
Note: Net Debt is negative, indicating a net cash position (Cash + Marketable Securities - Debt).
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $78.9 million (26.6%) driven by a 26% increase in RUCONEST® sales (U.S. volume up 20%) and a 29% increase in Joenja® sales (U.S. volume up 37%).
- Profitability: The company returned to profitability, reporting an operating profit of $25.8 million compared to an operating loss of $8.6 million in 2024. Net profit was $2.5 million compared to a net loss of $11.8 million.
- Acquisition: Completed the acquisition of Abliva AB in March 2025 for a total consideration of approximately $68.0 million, adding the napazimone (KL1333) asset. This resulted in significant intangible asset additions ($61.1 million for the license) and goodwill ($2.9 million).
- Cost Structure: Research and development expenses increased by 20.7% to $100.4 million, primarily due to the integration of the napazimone program. Marketing and sales expenses increased by 10.3% to $131.0 million due to commercial expansion.
- Strategic Shift: RUCONEST® was withdrawn from non-U.S. markets (representing <2% of revenue) to optimize capital allocation.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Liquidity: Management expects the year-end cash balance of $179.1 million to fund operations for more than 12 months.
- Joenja® Expansion: Focus on expanding access in the U.S. (pediatric label expansion pending FDA resubmission) and international markets (UK launch completed; EU approval expected Q2 2026; Japan approved for ages 4+).
- Pipeline Milestones: Top-line data for Phase II leniolisib studies in broader Primary Immunodeficiencies (PIDs) expected in H2 2026. Pivotal FALCON trial readout for napazimone expected in late 2027.
Key Risks and Contingencies:
- Customer Concentration: Two U.S. specialty pharmacies accounted for 77% of total revenues in 2025 ($290.9 million).
- Regulatory Uncertainty: The FDA issued a Complete Response Letter (CRL) in January 2026 regarding the pediatric sNDA for Joenja®, requesting additional pharmacokinetic data. Resubmission timing is pending FDA feedback.
- Competition: RUCONEST® faces competition from new prophylactic therapies approved in 2025 and potential gene therapies. Joenja® is currently the only approved therapy for APDS.
- Manufacturing: Reliance on third-party manufacturers (e.g., Sanofi, BioConnection) for both products creates supply chain risks.
Investor Verification Checklist
- Customer Concentration: Verify the stability of contracts with the two U.S. specialty pharmacies representing 77% of revenue.
- Regulatory Status (Joenja®): Monitor the timeline for resubmission of the pediatric sNDA following the January 2026 CRL and the expected EU Commission decision in Q2 2026.
- Acquisition Integration: Assess the progress of the Abliva AB integration and the clinical timeline for the napazimone (KL1333) FALCON trial.
- Patent Expiry: Review the patent landscape for RUCONEST® (U.S. patent protection and biologics exclusivity expire in 2026).
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive as the company scales commercial operations for Joenja® and invests in the pipeline.